High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT

心脏毒性 医学 封锁 蒽环类 随机对照试验 药理学 心脏病学 内科学 受体 化疗 癌症 乳腺癌
作者
Peter Henriksen,Morag MacLean,Marek Atter,Steff Lewis,Aryelly Rodríguez
出处
期刊:Efficacy and mechanism evaluation [NIHR Journals Library]
卷期号:: 1-73
标识
DOI:10.3310/aptu2400
摘要

Background Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by rises in plasma cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin-system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients receiving anthracycline chemotherapy. Methods In a multicentre prospective randomised open-label blinded end-point trial, patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy underwent plasma high-sensitivity cardiac troponin concentration monitoring and cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. Randomised controlled trial – patients at high risk of cardiotoxicity (plasma cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomised to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone. The primary end point was 6-month change in left ventricular ejection fraction. Prognostic cohort study – in low-risk non-randomised patients with plasma cardiac troponin I concentrations in the lower two tertiles, we hypothesised the absence of a 6-month change in left ventricular ejection fraction (± 2%). Results Between October 2017 and June 2021, 175 patients (mean age 53 years; 87% female; 71% breast cancer) were recruited. Patients randomised to cardioprotection ( n = 29) or standard care ( n = 28) had mean left ventricular ejection fractions of 65.7 ± 6.6% and 64.9 ± 5.9%, respectively, at 6 months. Twenty patients (68.9%) were adherent to cardioprotection therapy at 6 months. Adverse events were more commonly reported in the cardioprotection group, with 71.4% of patients having at least one adverse event compared with 12.7% non-randomised and 10.3% standard care patients. After adjusting for age, pre-treatment left ventricular ejection fraction and planned anthracycline dose, the estimated mean percentage-point difference in 6-month left ventricular ejection fraction between the cardioprotection and standard care groups was –0.4% (95% confidence interval –3.59 to 2.85%; p = 0.82). In low-risk non-randomised patients, baseline and 6-month left ventricular ejection fractions were 69.3 ± 5.7% and 66.4 ± 6.3%, respectively (estimated mean difference 2.9%, 95% confidence interval 1.45 to 4.28%; p = 0.92, not equivalent). The main secondary objective of demonstrating zero percentage-point change with equivalence of ± 2% was not met. Conclusions Combination candesartan and carvedilol therapy had no demonstrable cardioprotective effect in patients receiving anthracycline-based chemotherapy with high-risk on-treatment plasma cardiac troponin I concentrations. Low-risk non-randomised patients had similar modest declines in left ventricular ejection fraction, suggesting that the clinical utility of routine cardiac troponin monitoring remains undefined. The modest short-term declines in left ventricular ejection fraction suggest that early cardioprotection therapy has a limited role in patients receiving anthracycline-based chemotherapy. Limitations Treatment effect might have been influenced by several patients stopping cardioprotection treatment within 2 months of randomisation. Across all groups, reduction in left ventricular ejection fraction was lower than expected and patients with high-risk cardiac troponin I concentrations did not exhibit a greater fall in left ventricular ejection fraction than low-risk patients. These factors, together with the trial being powered to detect a 5-percentage-point change in left ventricular ejection fraction, mean that a small treatment effect was not excluded. Future work Future work should aim to understand the transition from small changes in cardiac function, 6 months after completion of anthracycline chemotherapy, to the late development of heart failure in this population. Trial registration This trial is registered as ISRCTN24439460 and EudraCT 2017-000896-99. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 15/48/20) and is published in full in Efficacy and Mechanism Evaluation ; Vol. 11, No. 12. See the NIHR Funding and Awards website for further award information.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小鹿飞飞发布了新的文献求助10
1秒前
FaFa发布了新的文献求助10
3秒前
raise发布了新的文献求助30
4秒前
小吴发布了新的文献求助10
4秒前
5秒前
英俊的铭的应助被可靠F采纳,获得10
5秒前
5秒前
希望天下0贩的0的应助被TGU采纳,获得10
5秒前
小马甲的应助被EmmaLei采纳,获得10
7秒前
小欣欣爱学习完成签到 ,获得积分10
8秒前
8秒前
无花果的应助被科研通管家采纳,获得10
8秒前
852的应助被科研通管家采纳,获得10
8秒前
桐桐的应助被科研通管家采纳,获得10
8秒前
隐形曼青的应助被科研通管家采纳,获得10
8秒前
我是老大的应助被科研通管家采纳,获得10
9秒前
9秒前
DW的应助被科研通管家采纳,获得10
9秒前
9秒前
丘比特的应助被科研通管家采纳,获得10
9秒前
FashionBoy的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
JamesPei的应助被科研通管家采纳,获得10
9秒前
思源的应助被科研通管家采纳,获得10
9秒前
hhhyl0217完成签到,获得积分10
10秒前
11秒前
dongfen发布了新的文献求助10
11秒前
天天快乐的应助被liu采纳,获得30
11秒前
12秒前
牛马完成签到,获得积分10
12秒前
小马甲的应助被开心德地采纳,获得100
12秒前
学霸业的应助被TreasureY采纳,获得10
12秒前
无极微光的应助被彪壮的凝海采纳,获得20
12秒前
不吃香菜发布了新的文献求助10
12秒前
云峰完成签到 ,获得积分10
12秒前
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189227
求助须知:如何正确求助?哪些是违规求助? 9576621
关于积分的说明 21849153
捐赠科研通 7787179
什么是DOI,文献DOI怎么找? 3435518
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482482